View Item 

Show simple item record

Treatment considerations in Helicobacter pylori management
dc.contributor.authorYang, Jyh-Chin
dc.contributor.authorKao, John Y.
dc.date.accessioned2022-02-07T20:23:39Z
dc.date.available2023-02-07 15:23:38en
dc.date.available2022-02-07T20:23:39Z
dc.date.issued2022-01
dc.identifier.citationYang, Jyh-Chin ; Kao, John Y. (2022). "Treatment considerations in Helicobacter pylori management." Alimentary Pharmacology & Therapeutics : S22-S28.
dc.identifier.issn0269-2813
dc.identifier.issn1365-2036
dc.identifier.urihttps://hdl.handle.net/2027.42/171560
dc.publisherWiley Periodicals, Inc.
dc.titleTreatment considerations in Helicobacter pylori management
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPharmacy and Pharmacology
dc.subject.hlbsecondlevelOtolaryngology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/171560/1/apt16652.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/171560/2/apt16652_am.pdf
dc.identifier.doi10.1111/apt.16652
dc.identifier.sourceAlimentary Pharmacology & Therapeutics
dc.identifier.citedreferenceSugimoto M, Shirai N, Nishino M, et al. Rabeprazole 10 mg q.d.s. decreases 24- h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype. Aliment Pharmacol Ther. 2012; 36: 627 - 634.
dc.identifier.citedreferenceVaira D, Zullo A, Vakil N, et al. Sequential therapy versus standard triple- drug therapy for Helicobacter pylori eradication. Ann Intern Med. 2007; 146: 556 - 563.
dc.identifier.citedreferenceYang JC, Lin CJ, Wang HL, et al. High- dose dual therapy is superior to standard first- line or rescue therapy for Helicobacter pylori infection. Clin Gastroenterol Hepatol. 2015; 13: 895 - 905.
dc.identifier.citedreferenceHsu PI, Tsay FW, Graham DY, et al. Equivalent efficacies of hybrid and bismuth quadruple therapies in eradication of Helicobacter pylori infection in a randomized controlled trial. Clin Gastroenterol Hepatol. 2018; 16: 1427 - 1433.
dc.identifier.citedreferenceHsu PI, Tsay FW, Kao JY, et al. Equivalent efficacies of reverse hybrid and concomitant therapies in first- line treatment of Helicobacter pylori infection. J Gastroenterol Hepatol. 2020; 35: 1731 - 1737.
dc.identifier.citedreferenceMalfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin- based triple therapy: a randomized, open- label, non- inferiority, phase 3 trial. Lancet. 2011; 377: 905 - 913.
dc.identifier.citedreferenceYang JC, Wang HL, Chen HD, et al. Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole- amoxicillin dual therapy for Helicobacter pylori eradication. Pharmacotherapy. 2011; 31: 227 - 238.
dc.identifier.citedreferenceYang JC, Lin CJ. CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor- based therapy of Helicobacter pylori infection. Expert Opin Drug Metab Toxicol. 2010; 6: 29 - 41.
dc.identifier.citedreferenceYang JC, Lu CW, Lin CJ. Treatment of Helicobacter pylori infection: Current status and future concepts. World J Gastroenterol. 2014; 20: 5283 - 5293.
dc.identifier.citedreferenceLi C, Shi Y, Baojun S, et al. PPI- amoxicillin dual therapy four times daily is superior to guidelines recommended regimens in the Helicobacter pylori eradication therapy within Asia: A systematic review and meta- analysis. Helicobacter. 2021; 26 ( 4 ): e12816.
dc.identifier.citedreferenceMurakami K, Sakurai Y, Shiino M, et al. Vonoprazan, a novel potassium- competitive acid blocker, as a component of first- line and second- line triple therapy for Helicobacter pylori eradication: a phase III, randomized, double- blind study. Gut. 2016; 65: 1439 - 1446.
dc.identifier.citedreferenceFuruta T, Yamade M, Kagami T, et al. Dual therapy with vonoprazan and amoxicillin is as effective as triple therapy with vonoprazan, amoxicillin and clarithromycin for eradication of Helicobacter pylori. Digestion. 2020; 101: 743 - 751.
dc.identifier.citedreferenceSuzuki S, Gotoda T, Kusano C, et al. Seven- day vonoprazan and low- dose amoxicillin dual therapy as first- line Helicobacter pylori treatment: a multicenter randomized trial in Japan. Gut. 2020; 69: 1019 - 1026.
dc.identifier.citedreferenceGraham DY, Canaan Y, Maher J, et al. Rifabutin- Based Triple Therapy (RHB- 105) for Helicobacter pylori Eradication: A Double- Blind, Randomized, Controlled Trial. Ann Intern Med. 2020; 172: 795 - 802.
dc.identifier.citedreferenceSavoldi A, Carrara E, Graham DY, et al. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta- analysis in world health organization regions. Gastroenterology. 2018; 155: 1372 - 1382.
dc.identifier.citedreferenceYang JC, Lin CJ, Li HM, et al. Genotypic testing is suboptimal to predict antibiotic resistance and therapeutic outcome for Helicobacter pylori eradication in clinical practice. Gastroenerology. 2016; 150 ( 4- Suppl 1 ): S- 73.
dc.identifier.citedreferenceDang BN, Graham DY Helicobacter pylori infection and antibiotic resistance: a WHO high priority? Nat Rev Gastroenterol Hepatol. 2017; 14: 383 - 384.
dc.identifier.citedreferenceCrowe SE. Helicobacter pylori infection. N Engl J Med. 2019; 380: 1158 - 1165.
dc.identifier.citedreferenceSurgano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015; 64: 1353 - 1367.
dc.identifier.citedreferenceMalfertheiner P, Megraud F, O- Morain CA, et al. Management of Helicobacter pylori infection - the Maastricht V/Florence Consensus Report. Gut. 2017; 66: 6 - 30.
dc.identifier.citedreferenceChey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017; 112: 212 - 238.
dc.identifier.citedreferenceFallone CA, Moss SF, Malfertheiner P. Reconciliation of recent Helicobacter pylori treatment guidelines in a time of increasing resistance to antibiotics. Gastroenterology. 2019; 157: 44 - 53.
dc.identifier.citedreferenceFock KM, Katelaris P, Sugano K, et al. Second Asia- Pacific consensus guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol. 2008; 24: 1587 - 1600.
dc.identifier.citedreferenceKuo YT, Liou JM, EI- Omar EM, et al. Primary antibiotic resistance in Helicobacter pylori in the Asia- Pacific region: a systematic review and meta- analysis. Lancet Gastroenterol Hepatol. 2017; 2: 707 - 715.
dc.identifier.citedreferenceTung CC, Hu CT, Lin CJ, et al. Efficacy of high- dose dual therapy and bismuth quadruple therapy in first- line and rescue Helicobacter pylori eradication - a final report of multi- center, randomized control study. Gastroenterology. 2021; 160 ( Suppl ): S- 115.
dc.identifier.citedreferenceMegraud F, Lamouliatte H. Review article: the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther. 2003; 17: 1333 - 1343.
dc.identifier.citedreferenceErah PO, Goddard AF, Barrett DA, et al. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother. 1997; 39: 5 - 12.
dc.identifier.citedreferenceLabenz J, Stolte M, Blum AL, et al. Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic ulcer patients with omeprazole and amoxicillin. Gut. 1995; 37: 39 - 43.
dc.identifier.citedreferenceFuruta T, Shirai N, Takashima M, et al. Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics. 2001; 11: 341 - 348.
dc.identifier.citedreferenceScott D, Weeks D, Melchers K, Sachs G. The life and death of Helicobacter pylori. Gut. 1998; 43 ( suppl 1 ): S56 - S60.
dc.identifier.citedreferenceTan B, Yang JC, Young CL, et al. Helicobacter pylori antimicrobial susceptibility testing- guided salvage therapy in the USA: a real life experience. Dig Dis Sci. 2018; 63: 437 - 445.
dc.identifier.citedreferenceGraham DY, Fischbach L Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010; 59: 1143 - 1153.
dc.identifier.citedreferenceFischbach LA, van Zanten SV, Dickason J. Meta- analysis: the efficacy, adverse events, and adherence related to first- line anti- Helicobacter pylori quadruple therapies. Aliment Pharmacol Ther. 2004; 20: 1071 - 1082.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
apt16652.pdf
Size:
542.9KB
Format:
PDF
View/Open
Name:
apt16652_am.pdf
Size:
283.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.